90101-22-7

Basic information

• Product Name: 2-(BOC-AMINO)-6-PICOLINE
• Synonyms: 2-(BOC-AMINO)-6-PICOLINE;TERT-BUTYL 6-METHYLPYRIDIN-2-YLCARBAMATE;Carbamic acid, (6-methyl-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI);2-Amino-6-methylpyridine, N-BOC protected;2-Amino-6-picoline, N-BOC protected;2-Amino-6-methylpyridine, 2-BOC protected 97%;tert-Butyl (6-methylpyridin-2-yl)carbamate, 2-Amino-6-picoline, 2-BOC protected;tert-butyl 6-Methylpyridine-2-ylcarbaMate
• CAS NO: 90101-22-7
• Molecular Formula: C₁₁H₁₆N₂O₂
• Molecular Weight: 208.26
• Product Categories: N-BOC
• Mol File: 90101-22-7.mol

Chemical Properties

• Melting Point: 63-64°C
• Boiling Point: 261.4°Cat760mmHg
• Flash Point: 111.9°C
• Appearance: /
• Density: 1.108g/cm³
• Vapor Pressure: 0.0116mmHg at 25°C
• Refractive Index: 1.54
• Storage Temp.: 2-8°C
• PKA: 12.56±0.70(Predicted)
• CAS DataBase Reference: 2-(BOC-AMINO)-6-PICOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(BOC-AMINO)-6-PICOLINE(90101-22-7)
• EPA Substance Registry System: 2-(BOC-AMINO)-6-PICOLINE(90101-22-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-43
• Safety Statements: 36/37
• WGK Germany: 3
• Hazardous Substances Data: 90101-22-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
2-(BOC-AMINO)-6-PICOLINE is used as a reagent in the synthesis of various drugs and pharmaceuticals. Its versatile reactivity and potential for selective functionalization make it a valuable intermediate in the production of bioactive compounds.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(BOC-AMINO)-6-PICOLINE is employed as a key building block for the creation of complex organic molecules. Its presence of the BOC protecting group allows for controlled reactions, facilitating the synthesis of target compounds with specific functional groups.
Used in the Production of Bioactive Compounds:
2-(BOC-AMINO)-6-PICOLINE is utilized as an important intermediate in the synthesis of bioactive compounds, contributing to the development of new therapeutic agents and pharmaceuticals with potential applications in various medical fields.

InChI:InChI=1/C11H16N2O2/c1-8-6-5-7-9(12-8)13-10(14)15-11(2,3)4/h5-7H,1-4H3,(H,12,13,14)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1824-81-3 2-Amino-6-methylpyridine 
• 75-44-5 phosgene 
• 75-65-0 tert-butyl alcohol 
• 34619-03-9 tert-butyldicarbonate 
• 75-09-2 dichloromethane 
• 121-44-8 triethylamine 

Downstream Products

• 205676-84-2 (tert-butoxy)-N-methyl-N-[6-methyl-(2-pyridyl)]carboxamide 
• 400781-16-0 tert-butyl (6-(bromomethyl)pyridin-2-yl)carbamate 
• 402933-56-6 [6-(2-hydroxyethyl)-2-pyridinyl]carbamic acid,1,1-dimethylethyl ester 
• 1338469-87-6 2-(N-benzoyl-N-(t-butoxycarbonyl)-amino)-6-methyl-pyridine-N-oxide 
• 1187836-93-6 picarbutrazox 
• 1334119-54-8 C₂₇H₂₇N₇O₄ 
• 1334119-52-6 t-butyl benzoyl-{6-((Z)-(1-methyl-1H-5-tetrazolyl)phenylmethylene-aminooxymethyl)-2-pyridyl}carbamate 
• 500207-04-5 tert-butyl N-[6-({[(Z)-[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)(phenyl)methylidene]amino]oxy}methyl)pyridin-2-yl]carbamate 
• 1334119-10-6 t-butyl benzoyl-(6-bromomethyl-pyridin-2-yl)-carbamate 

Relevant articles and documents

ARYL AND HETEROARYL-CARBOXAMIDE SUBSTITUTED HETEROARYL COMPOUNDS AS TYK2 INHIBITORS

Novel carboxamide substituted compounds of Formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Tyrosine Kinase 2 (Tyk2).

Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer’s Agents Based on Rational Design

Glutaminyl cyclase (QC) has been implicated in the formation of toxic amyloid plaques by generating the N-terminal pyroglutamate of β-amyloid peptides (pGlu-Aβ) and thus may participate in the pathogenesis of Alzheimer’s disease (AD). We designed a library of glutamyl cyclase (QC) inhibitors based on the proposed binding mode of the preferred substrate, Aβ3E?42. An in vitro structure-activity relationship study identified several excellent QC inhibitors demonstrating 5- to 40-fold increases in potency compared to a known QC inhibitor. When tested in mouse models of AD, compound 212 significantly reduced the brain concentrations of pyroform Aβ and total Aβ and restored cognitive functions. This potent Aβ-lowering effect was achieved by incorporating an additional binding region into our previously established pharmacophoric model, resulting in strong interactions with the carboxylate group of Glu327 in the QC binding site. Our study offers useful insights in designing novel QC inhibitors as a potential treatment option for AD.

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS

Compounds of formula (Ι') that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Optimizing the physicochemical properties of Raf/MEK inhibitors by nitrogen scanning

Substituting a carbon atom with a nitrogen atom (nitrogen substitution) on an aromatic ring in our leads 11a and 13g by applying nitrogen scanning afforded a set of compounds that improved not only the solubility but also the metabolic stability. The impa

PROCESS FOR PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS

Provided is a process for the preparation of t-butoxycarbonylamine compounds, which comprises using phosgene or a phosgene equivalent, t-butanol, and an organic base. Even when applied to a primary or secondary amine compound having low nucleophilicity, the process enables highly selective preparation of a t-butoxycarbonylamine compound at a low cost. In the process, a t-butoxycarbonylamine compound is prepared using: phosgene or a phosgene equivalent; t-butanol; an organic base; and either a primary or secondary amine compound or a primary or secondary ammonium salt.

2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system.

2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun

2,6-DIAMINOPYRIDINE COMPOUNDS SUITABLE FOR TREATING DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS OR FOR TREATING OR PREVENTING OCULAR DISEASES OR CONDITIONS ASSOCIATED WITH A PATHOLOGICAL ABNORMALITY/CHANGE IN THE TISSUE OF THE VISUAL SYSTEM

The present invention relates to 2.6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun

Structure-based design, synthesis, and biological evaluation of lipophilic-tailed monocationic inhibitors of neuronal nitric oxide synthase

Selective inhibitors of neuronal nitric oxide synthase (nNOS) have the potential to develop into new neurodegenerative therapeutics. Recently, we described the discovery of novel nNOS inhibitors (1a and 1b) based on a cis-pyrrolidine pharmacophore. These compounds and related ones were found to have poor blood-brain barrier permeability, presumably because of the basic nitrogens in the molecule. Here, a series of monocationic compounds was designed on the basis of docking experiments using the crystal structures of 1a,b bound to nNOS. These compounds were synthesized and evaluated for their ability to inhibit neuronal nitric oxide synthase. Despite the excellent overlap of these compounds with 1a,b bound to nNOS, they exhibited low potency. This is because they bound in the nNOS active site in the normal orientation rather than the expected flipped orientation used in the computer modeling. The biphenyl or phenoxyphenyl tail is disordered and does not form good protein-ligand interactions. These studies demonstrate the importance of the size and rigidity of the side chain tail and the second basic amino group for nNOS binding efficiency and the importance of the hydrophobic tail for conformational orientation in the active site of nNOS.

Peripheral but crucial: A hydrophobic pocket (Tyr706, Leu 337, and Met336) for potent and selective inhibition of neuronal nitric oxide synthase

Selective inhibition of the neuronal isoform of nitric oxide synthase (nNOS) over endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) has become a promising strategy for the discovery of new therapeutic agents for neurodege